ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12, Zacks reports.
ProMIS Neurosciences Price Performance
NASDAQ:PMN traded down $0.04 during trading hours on Wednesday, hitting $0.71. The stock had a trading volume of 56,572 shares, compared to its average volume of 70,763. The firm has a market capitalization of $23.24 million, a price-to-earnings ratio of -7.11 and a beta of 0.58. ProMIS Neurosciences has a one year low of $0.62 and a one year high of $2.61. The company has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.96.
Analysts Set New Price Targets
Separately, Guggenheim reissued a “buy” rating and set a $6.00 price objective on shares of ProMIS Neurosciences in a report on Tuesday.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Recommended Stories
- Five stocks we like better than ProMIS Neurosciences
- What Are Dividend Challengers?
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- The 3 Best Retail Stocks to Shop for in August
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Growth Stocks: What They Are, Examples and How to Invest
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
